{"id":2311,"date":"2015-01-01T12:01:00","date_gmt":"2015-01-01T11:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2015\/neues-onkologisches-arzneimittel-idelalisib-zydelig"},"modified":"2015-01-01T12:01:00","modified_gmt":"2015-01-01T11:01:00","slug":"neues-onkologisches-arzneimittel-idelalisib-zydelig","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2015\/neues-onkologisches-arzneimittel-idelalisib-zydelig","title":{"rendered":"Neues onkologisches Arzneimittel: Idelalisib (Zydelig\u00ae)"},"content":{"rendered":"<p>Wir hatten anl\u00e4sslich der Zulassung von Ibrutinib (Imbrovica\u00ae) vor kurzem \u00fcber eine neue Klasse von Wirkstoffen berichtet, die gezielt die Signal\u00fcbertragung \u00fcber den B-Zell-Rezeptor (B-cell receptor = BCR) unterbrechen (1). An diese neue Wirkstoffklasse werden gro\u00dfe Hoffnungen gekn\u00fcpft, denn sie unterbrechen nicht nur die f\u00fcr das \u00dcberleben reifer maligner B-Zellen notwendigen Signalwege, sondern verhindern auch [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wir hatten anl\u00e4sslich der Zulassung von Ibrutinib (Imbrovica\u00ae) vor kurzem \u00fcber eine neue Klasse von Wirkstoffen berichtet, die gezielt die Signal\u00fcbertragung \u00fcber den B-Zell-Rezeptor (B-cell receptor = BCR) unterbrechen (1). An diese neue Wirkstoffklasse werden gro\u00dfe Hoffnungen gekn\u00fcpft, denn sie unterbrechen nicht nur die f\u00fcr das \u00dcberleben reifer maligner B-Zellen notwendigen Signalwege, sondern verhindern auch [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1358,1378,4567,4596,1990,4597,1394],"class_list":["post-2311","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-b-zell-lymphom","tag-b-zell-non-hodgkin-lymphom","tag-b-zell-rezeptor","tag-chronische-lymphytische-leukaemie","tag-follikulaeres-lymphom","tag-idelalisib","tag-non-hodgkin-lymphom"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2311"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2311\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}